Is Cytosorbents Crp (CTSO) overvalued? · $28.8M cap
Cytosorbents Crp (CTSO) is a medical devices company listed on US.
This page asks whether Cytosorbents Crp (CTSO) looks expensive on cached numbers — not a short thesis.
No cached income statement for CTSO, so there is no earnings base to call rich or cheap.
CTSO currently screens at market cap $28.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CTSO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CTSO stock page for the full model, not this heading.
Not investment advice.